Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2...

por Ritzel, R, Roussel, R, Bolli, G B, Vinet, L, Brulle-Wohlhueter, C, Glezer, S, Yki-Järvinen, H
Publicado 2015

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insu...

por Riddle, M C, Yki-Järvinen, H, Bolli, G B, Ziemen, M, Muehlen-Bartmer, I, Cissokho, S, Home, P D
Publicado 2015

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly

por Varewijck, A. J., Janssen, J. A. M. J. L., Vähätalo, M., Hofland, L. J., Lamberts, S. W. J., Yki-Järvinen, H.
Publicado 2012

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaem...

por Yki‐Järvinen, H., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Wardecki, M., Muehlen‐Bartmer, I., Maroccia, M., Riddle, M. C.
Publicado 2015